Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04457232

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Prostate Cancer: A Prospective Exploratory Biodistribution Study With Histopathology Validation

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Jonsson Comprehensive Cancer Center · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers including prostate cancer.

Detailed description

PRIMARY OBJECTIVE: I. To define the biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues of patients with prostate cancer. SECONDARY OBJECTIVES: I. To evaluate whether 68Ga-FAPi-46 and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) accumulation observed by positron emission tomography (PET) correlates with the amount of fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) in excised cancer tissue, respectively. II. To assess the 68Ga-FAPI-46 biodistribution correlation with 68Ga-PSMA-11. OUTLINE: Patients receive 68Ga-FAPi-46 intravenously (IV) and undergo PET/computed tomography (CT) imaging over 20-50 minutes.

Conditions

Interventions

TypeNameDescription
PROCEDUREComputed TomographyUndergo PET/CT imaging
OTHERGallium Ga 68 FAPi-46Given IV
PROCEDUREPositron Emission TomographyUndergo PET/CT imaging

Timeline

Start date
2020-09-09
Primary completion
2023-05-30
Completion
2026-05-30
First posted
2020-07-07
Last updated
2025-07-15

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04457232. Inclusion in this directory is not an endorsement.